PRONOUNCE: Randomized, open-label, phase 3 study of pemetrexed (Pem) + carboplatin (Cb) followed by maintenance pemetrexed vs. paclitaxel (Pac) + carboplatin + bevacizumab (Bev) followed by maintenance bevacizumab in patients with advanced non-squamous non-small-cell lung cancer (NS-NSCLC)
R Zinner1, HJ Ross2, RW Weaver3,13, R Govindan4, VR Holden5, NM Chowhan6, T Beck7, DM Waterhouse8,13, MR Modiano9, VP Rao10, J Liu11, AG Koustenis11, SA Melemed11, SC Guba11, WI Ortuzar11, D Desaiah11,
DR Spigel12,13, CK Obasaju11
1University of Texas MD Anderson Cancer Center, Houston, TX; 2Mayo Clinic Arizona, Scottsdale, AZ; 3Florida Cancer Specialists, Fort Myers, FL; 4Washington University Medical School, St. Louis, MO; 5St Johns Clinic Cancer and Hematology, Springfield, MO; 6Floyd Memorial Cancer Center of Indiana, New Albany, IN; 7Highlands Oncology Group, Fayettville, AR; 8Oncology Hematology Care Inc., Blue Ash, OH; 9ACRC/Arizona Clinical Research Center, Arizona Oncology, Tucson, AZ; 10Mid Dakota Clinic Hematology and Oncology, Bismarck, ND; 11Eli Lilly pany, Indianapolis, IN; 12Tennessee Oncology, Nashville, TN; 13Sarah Cannon Research Institute, Nashville, TN
1Scagliotti GV, et al. J Clin Oncol 2008;26:3543-3551.; 2Ciuleanu TE, et al. Lancet 2009;Online Pub 09 Sept.; 3Hanna N, et al. J Clin Oncol 2004;22:1589-1597.; 4Peterson P, et al. J Thorac Oncol 2007;2(8):s851.; 5Sandler A, et al. N EnglJ Med 2006;355:2542-2550.; 6Scagliotti GV, et al. Clin Cancer Res 2005;11(2 Pt1):690-696.; 7Zinner RG, et al. Cancer 2005; 104(11):2449-2456.
PRONOUNCE: Background
Pemetrexed bination with cisplatin is efficacious in the first-line treatment of nonsquamous NSCLC1
Pemetrexed as monotherapy improves overall survival when given in the maintenance setting2 or as second-line therapy3,4
Pemetrexed plus carboplatin5,6 and paclitaxel plus carboplatin and bevacizumab7 are efficacious regimens studied in this setting
These bination regimens have not been pared; available data sug
晚期非鳞非小细胞肺癌治疗的临床研究 来自淘豆网m.daumloan.com转载请标明出处.
